BACE1 and Alzheimer disease: Adalimumab significantly attenuated neuronal damage and neuroinflammation, decreased beta secretase-1 protein expression and Aβ1-40 plaques, and improved cognitive functions in Aβ1-40-injected mice [351,352], suggesting possible clinically meaningful outcomes in patients with AD.